Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (181-190 of 242) with videos related to

Pageof 25
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialRoss A Soo, Eng Huat Tan, Hidetoshi Hayashi, et al.
Cancer Science|July 19, 2020
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global studyTakashi Seto, Hidetoshi Hayashi, Miyako Satouchi, et al.
JTO Clinical and Research Reports|October 17, 2022
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With <i>ROS1</i>-Positive Advanced NSCLCYi-Long Wu, Shun Lu, James Chih-Hsin Yang, et al.
Cancer Science|September 21, 2020
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAYMakoto Nishio, Takashi Seto, Martin Reck, et al.
Investigational New Drugs|February 1, 2017
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapyYuichi Tambo, Yukio Hosomi, Hiroshi Sakai, et al.
Translational Lung Cancer Research|July 10, 2023
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced <i>EGFR</i>non-small-cell lung cancerMakoto Nishio, Shinji Atagi, Koichi Goto, et al.
The Lancet. Oncology|October 13, 2025
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 studyAkito Hata, Taira Ninomaru, Hideaki Okada, et al.
Translational Lung Cancer Research|February 11, 2021
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)Shinji Takeuchi, Noriko Yanagitani, Takashi Seto, et al.
JTO Clinical and Research Reports|November 24, 2025
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLCMakoto Nishio, Takashi Seto, Martin Reck, et al.
American Journal of Clinical Oncology|March 10, 2018
Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809Seiji Niho, Norihiko Ikeda, Hiroshi Michimae, et al.
Pageof 25

Showing results (181-190 of 242) with videos related to

Sort By:
Pageof 25
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialRoss A Soo, Eng Huat Tan, Hidetoshi Hayashi, et al.
Cancer Science|July 19, 2020
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global studyTakashi Seto, Hidetoshi Hayashi, Miyako Satouchi, et al.
JTO Clinical and Research Reports|October 17, 2022
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With <i>ROS1</i>-Positive Advanced NSCLCYi-Long Wu, Shun Lu, James Chih-Hsin Yang, et al.
Cancer Science|September 21, 2020
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAYMakoto Nishio, Takashi Seto, Martin Reck, et al.
Investigational New Drugs|February 1, 2017
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapyYuichi Tambo, Yukio Hosomi, Hiroshi Sakai, et al.
Translational Lung Cancer Research|July 10, 2023
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced <i>EGFR</i>non-small-cell lung cancerMakoto Nishio, Shinji Atagi, Koichi Goto, et al.
The Lancet. Oncology|October 13, 2025
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 studyAkito Hata, Taira Ninomaru, Hideaki Okada, et al.
Translational Lung Cancer Research|February 11, 2021
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)Shinji Takeuchi, Noriko Yanagitani, Takashi Seto, et al.
JTO Clinical and Research Reports|November 24, 2025
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLCMakoto Nishio, Takashi Seto, Martin Reck, et al.
American Journal of Clinical Oncology|March 10, 2018
Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809Seiji Niho, Norihiko Ikeda, Hiroshi Michimae, et al.
Pageof 25